Trends in healthcare are driven by innovation, which is largely being driven by specialty innovation, Douglas M. Long, MBA, vice president of industry relations at IMS Health, said during the headline session "Marketplace Trends" at the Academy of Managed Care Pharmacy's 27th Annual Meeting & Expo.
As more high-cost drugs reach the market, the meaning of value gains more attention, especially in the specialty pharmacy market. One way to assess value is to use a cost-effectiveness analysis to guide formulary decisions.
The way drugs are priced should have less in common with healthcare services and more in common with a consumer product like a computer operating system, Dana Goldman, PhD, the Leonard D. Schaeffer Chair and Director of the Schaeffer Center for Health Policy and Economics at the University of Southern California, said at AMCP's 27th Annual Meeting & Expo in San Diego on April 7-10.
Employers who manage the high cost of care associated with specialty pharmacy face a number of challenges that are being addressed by the National Employer Initiative on Specialty Pharmacy, said Cheryl Larson, BA, vice president of the Midwest Business Group on Health.
The Cardio-Oncology Intensive during the Annual Scientific Session of the American College of Cardiology reflects the increased need for improved diagnostic tools and cardioprotective strategies as cancer patients live longer. Besides a second malignancy, heart disease accounts for most morbidity and death in cancer survivors.
A study that combined socioeconomic data and hospital-level data on quality care after myocardial infarction showed that hospitals that serve the poorest Americans adhere to high standards, but patient outcomes do not always reflect that high-quality acute care.
The study drug, Bendavia, was developed to improve mitochondrial response when oxygen returns to the tissue affected by a heart attack. Results showed some improvement, but not at levels that were statistically significant.
Patients in the study were given support through a weight loss clinic for a 4-year period. Those who had sustained weight lost and did not let their weight fluctuate were most likely to have arrythmia-free survival.
Amgen's cholesterol-fighting PCSK9 inhibitor was shown to reduce the likelihood that patients would suffer cardiovascular events. The question now is whether FDA will grant approval soon and how widely the drug will be used, given speculation about its cost.
Identifying which patients with diabetes will develop heart disease is not as straightforward as it might seem. This session explored the use of biomarkers, imaging, and how a population health-based model will do a better job of identifying women at risk.
Cardiologists treat patients who are older, sicker, and more reliant on Medicare. That means they must pay attention to new payment models from CMS that reduce reliance on fee-for-service and increase the presence of accountable care organizations.
Results from a study of long-term use of this dual anti-platelet therapy suggest patients may be able to switch to a 60 mg dose at the 1 year mark after a heart attack, rather than 90 mg.
A head-to-head comparison found patients receiving heart CT scans fared about as well as those receiving a variety of functional tests, although CT did a better job of identifying those who needed follow-up procedures. The study's lead author predicts a change in clinical guidelines, although critics question whether patients should receive so much radiation.
During the session "Principles of Immunotherapy" at the National Comprehensive Cancer Network 20th Annual Conference, Anthony J. Olszanski, RPh, MD, from the Fox Chase Cancer Center, described the complex interplay between the immune system and cancer, and some of the current immunotherapies being used today.
Over the years, the National Comprehensive Cancer Network Guidelines have become the market leader for clinical guidelines to consult, but with that success comes responsibility and scrutiny, according to Clifford Goodman, PhD.
The National Comprehensive Cancer Network Guidelines bring the practices of cancer care thought leaders out to the community, said Mary Lou Smith, JD, MBA, co-founder of the Research Advocacy Network.
The most recent Surgeon General Report on Smoking and Health initiated the decision to create smoking cessation guidelines for cancer patients, Peter G. Shields, MD, said during his session announcing the new NCCN Guidelines.
Patient-provider dialogue before making treatment decisions affects how satisfied patients are with their overall care, Linda House, RN, BSN, MSM, president of the Cancer Support Community, said at the National Comprehensive Cancer Network 20th Annual Conference.
Resource constraints may confine the ability of physicians to deliver optimal cancer care to all patients across the world, which the National Comprehensive Cancer Network is acknowledging by resource stratifying its Guidelines.
While the cost of introductory cancer drugs is increasing rapidly, there has not been a commensurate increase in benefit, according to Peter Bach, MD, with Memorial Sloan Kettering Cancer Center.
The roundtable discussion on the second day of the National Comprehensive Cancer Network 20th Annual Conference spent a long time defining value in cancer care and how it can be incorporated into healthcare decision making.
Patients are looking for more transparency when it comes to their treatment options so they can make informed decisions and "take control of their journey," Kim Thiboldeaux, chief executive officer of the Cancer Support Community, said at the National Comprehensive Cancer Network 20th Annual Conference.
When the first National Comprehensive Cancer Network Guidelines were developed 20 years ago, even the participating members who were there at the beginning were skeptical they would be able to come to an agreement and build something lasting.
The National Comprehensive Cancer Network (NCCN) Guidelines may be successful historically, but the network isn't resting on its laurels, Robert Carlson, MD, chief executive officer, said at the NCCN 20th Annual Meeting.
During his keynote speech at the National Comprehensive Cancer Network (NCCN)'s 20th Annual Conference, Chief Executive Officer Robert Carlson, MD, spent the majority of his time discussing the NCCN Guidelines because they are the core of its services.
Monday's oral abstract sessions on multiple myeloma at the Annual Meeting of the American Society of Hematology featured final phase 1b/2 results on the elotuzumab combination that received breakthrough therapy status from FDA earlier this year.
Pomalidomide was approved by FDA in February 2013 for multiple myeloma patients whose disease has progressed despite having received at least 2 other therapies. On Monday, researchers at the American Society of Hematology Annual Meeting presented results of phase 2 studies on combinations with the immunomodulatory drug.
On the second day of the 56th Annual Meeting of the American Society of Hematology, held December 6-9 in San Francisco, a session on tyrosine kinase inhibitors in treating chronic myelogenous leukemia included 5-year follow-up results from the DASISION trial and recognizing failure for major molecular response to guide treatment modification.
At an education session at the American Society of Hematology Annual Meeting, Christopher R. Flowers, MD, MS, discussed current thinking in the use of routine imaging for patients who have achieved a long-term complete response in non-Hodgkin lymphoma.
The plenary session on the second day of the 56th Annual Meeting of the American Society of Hematology, held December 6-9 in San Francisco, saw the best presentations, selected by the Program Committee, from among the thousands of scientific abstracts that were accepted for the meeting. These talks included a JAK/STAT-mediated thrombopoietin regulation by the Ashwell-Morell receptor, lenalidomide-mediated casein kinase regulation in myelodysplastic syndrome, and the results of the SORAML trial in acute myeloid leukemia.
